SLC39A7 upregulation links to skin fibrosis in systemic sclerosis via TGF-β/SMAD pathway.
Xu WenJun AoiTselmeg MijeeIkko KajiharaKatsunari MakinoSatoshi FukushimaPublished in: The Journal of dermatology (2024)
Systemic sclerosis (SSc) is a multisystem connective tissue disease. Skin fibrosis, the hallmark of this disease, is defined as the excess deposition and accumulation of extracellular matrix, mainly type 1 collagen, in the dermis. SLC39A7 is an intracellular zinc transporter that plays a unique role in connective tissue formation. Therefore, we investigated the expression and role of SLC39A7 in SSc. Using immunohistochemical staining we demonstrated the overexpression of SLC39A7 in the skin of SSc patients. Quantitative real-time PCR and western blot data analysis showed that both SLC39A7 mRNA and protein levels were significantly upregulated in dermal fibroblasts from SSc patients compared to healthy controls. We used the shRNA lentiviral particle transduction system to stably knockdown the expression of SLC39A7 in SSc fibroblasts. The results showed that knockdown of SLC39A7 suppressed the production of type 1 collagen. These findings provide evidence that SLC39A7 is involved in the pathogenesis of SSc and that SLC39A7 plays a positive role in its progression.
Keyphrases
- systemic sclerosis
- extracellular matrix
- end stage renal disease
- interstitial lung disease
- poor prognosis
- wound healing
- data analysis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- binding protein
- transforming growth factor
- real time pcr
- mass spectrometry
- epithelial mesenchymal transition
- long non coding rna
- signaling pathway
- high resolution
- flow cytometry
- patient reported
- tissue engineering
- amino acid